Neurocrine Biosciences advertising spend, FY2025
Neurocrine Biosciences (NBIX) reported $227M of advertising expense for the fiscal year ended Dec 31, 2025. That is 7.9% of revenue of $2.9B. Up 18.7% from FY2024.
Key facts
- Ad spend is 3.5x its FY2020 level ($64.8M), faster than revenue (2.7x).
- FY2025 is the highest year on file, going back to FY2018.
- Largest increase +115.7% in FY2021.
- Ad spend has risen 7 years in a row.
- Ad spend is 7.9% of revenue, up from 6.2% in FY2020.
- Neurocrine Biosciences spends more on advertising than 54% of the 458 US-listed companies tracked. Its ad-to-revenue ratio is 1.7x the median of 4.5%.
Ad spend by fiscal year
Ad spend as % of revenue
Ad spend in context, FY2025
Advertising was 19.6% of selling, general and administrative expense. Research and development spending was 4.5x advertising. Advertising equalled 36.6% of operating income.
| Advertising | $227M | AdvertisingExpense |
|---|---|---|
| Selling, general and administrative | $1.2B | ad spend = 19.6% |
| Research and development | $1B | R&D = 4.5x ad spend |
| Operating income | $619M | ad spend = 36.6% |
| Net income | $479M |
Same fiscal year and filing as the ad spend. Selling and marketing and SG&A usually include advertising.
History
Download CSV| Fiscal year | Period end | Ad spend | YoY | Revenue | Ad / revenue | Tag | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | $227M | +18.7% | $2.9B | 7.9% | AdvertisingExpense | 10-K Feb 11, 2026 |
| FY2024 | Dec 31, 2024 | $191M | +19.4% | $2.4B | 8.1% | AdvertisingExpense | 10-K Feb 11, 2026 |
| FY2023 | Dec 31, 2023 | $160M | +6.8% | $1.9B | 8.5% | AdvertisingExpense | 10-K Feb 11, 2026 |
| FY2022 | Dec 31, 2022 | $150M | +7.1% | $1.5B | 10.1% | AdvertisingExpense | 10-K Feb 10, 2025 |
| FY2021 | Dec 31, 2021 | $140M | +115.7% | $1.1B | 12.3% | AdvertisingExpense | 10-K Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $64.8M | +59.6% | $1B | 6.2% | AdvertisingExpense | 10-K Feb 9, 2023 |
| FY2019 | Dec 31, 2019 | $40.6M | +98.0% | $788M | 5.2% | AdvertisingExpense | 10-K Feb 11, 2022 |
| FY2018 | Dec 31, 2018 | $20.5M | n/a | $451M | 4.5% | AdvertisingExpense | 10-K Feb 5, 2021 |
Ad spend, revenue and the ratio come from the linked filing. YoY compares each year with the fiscal year directly before it, under the same tag. A gap, a change of tag or a change of fiscal year end leaves it blank.
What the figure is
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Compared with similar spenders
The 6 companies closest to Neurocrine Biosciences in latest-year ad spend.
| Rank | Company | Ad spend | Ad / revenue | YoY | Fiscal year |
|---|---|---|---|---|---|
| 209 | Hertz Global | $230M | 2.7% | -12.9% | FY2025 |
| 210 | Grand Canyon Education | $229M | 20.7% | +7.9% | FY2025 |
| 211 | Garmin | $229M | 3.2% | +19.3% | FY2025 |
| 212 | Neurocrine Biosciences | $227M | 7.9% | +18.7% | FY2025 |
| 213 | McCormick | $225M | 3.3% | +2.9% | FY2025 |
| 214 | Peloton Interactive | $224M | 9.2% | -9.2% | FY2026 |
| 215 | Dexcom | $224M | 4.8% | +15.2% | FY2025 |
Full ranking of 458 companies · Biggest increases #120 · Up 5+ years in a row #22
Questions
How much does Neurocrine Biosciences spend on advertising?
Neurocrine Biosciences spent $227M on advertising in fiscal 2025, the year ended Dec 31, 2025, according to its 10-K filed Feb 11, 2026.
What percentage of revenue does Neurocrine Biosciences spend on advertising?
7.9% of revenue in fiscal 2025 ($227M against $2.9B). The median across the 458 companies tracked is 4.5%.
Is Neurocrine Biosciences spending more on advertising?
Yes. Ad spend rose 18.7% in fiscal 2025 from fiscal 2024. It has risen 7 years in a row.
How does Neurocrine Biosciences rank by advertising spend?
#212 of 458 US-listed companies with $50M or more in ad spend, ranked on each company's latest fiscal year.
Does Neurocrine Biosciences spend more on advertising than on R&D?
No. In fiscal 2025 it spent $1B on research and development and $227M on advertising.
What does Neurocrine Biosciences's advertising figure include?
Advertising costs as disclosed in the annual report (XBRL tag AdvertisingExpense).
Company and source
- Filing
- 10-K for FY2025, filed Feb 11, 2026
- Accession number
0000914475-26-000007- Company
- NEUROCRINE BIOSCIENCES INC, CIK 914475, SIC 2836 (Biological Products, (No Diagnostic Substances))
- Headquarters
- San Diego, CA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Listed on
- Nasdaq
- SEC filer status
- Large accelerated filer
- Data
- SEC EDGAR XBRL company facts, retrieved Nov 18, 2026. Methodology.
- Cite
- Neurocrine Biosciences advertising spend, FY2018-FY2025. Aleksei Trudov, io.trudov.com, from SEC EDGAR XBRL company facts (latest: 10-K filed Feb 11, 2026), retrieved Nov 18, 2026. https://io.trudov.com/company/neurocrine-biosciences/advertising-spend/
- Download
- CSV, all years · CSV, all 458 companies